Christopher Bowden
CIK: 0001608601
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
BCAX
Bicara Therapeutics Inc.
Director
Discretionary Trading P&L
Holdings
About Bowden Christopher
Bowden Christopher (SEC CIK 0001608601) files insider reports with the SEC as Director of Bicara Therapeutics Inc. (BCAX).
Signal8 holds 3 ownership filings by Bowden Christopher (1 Form 3, 2 Form 4), filed between Sep 12, 2024 and Jun 10, 2026. Those filings report 2 transactions, from Jun 9, 2025 to Jun 9, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Bowden Christopher's filings is in BOSTON, MA.
Recent filings by Bowden Christopher
Other insiders filing for Bicara Therapeutics Inc. (BCAX)
- Cohlhepp Ryan, President, COO & Interim CEO
- Larson Jennifer, Chief Financial Officer
- Hyep Ivan, Chief Financial Officer
- Mazumdar Claire, Chief Executive Officer
- Bender Jeremy, Director
- Oliger Christy J., Director